Mind Medicine Mindmed Inc (MNMD)

$11.34 -0.19 (-1.65%)
Market Cap 877.30M
Revenue (ttm) 0.00
Net Income (ttm) -108.68M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.22
Volume 1,478,200
Avg Vol 1,879,528
Day's Range N/A - N/A
Shares Out 76.09M
Stochastic %K 6%
Beta 2.57
Analysts Strong Sell
Price Target $24.91

Company Profile

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is head...

Industry: Biotechnology
Sector: Healthcare
Phone: 212 220 6633
Address:
One World Trade Center, Suite 8500, New York, United States
Kaloo_03
Kaloo_03 Nov. 7 at 12:06 AM
$MNMD
1 · Reply
NeedsAwin
NeedsAwin Nov. 6 at 11:24 PM
$MNMD well that was a nothing burger. Not bad not good. Just nothing.
0 · Reply
goral17
goral17 Nov. 6 at 10:52 PM
$MNMD Too much dilution. Too many reverse splits. Too many mumbo jumbo naming of products. Too scammy? I think so... This gets delisted within a couple years! Back to otc! If trump gets a 3rd term I think theyll send this shit BACK to the Canadian exchanges!
1 · Reply
goral17
goral17 Nov. 6 at 10:45 PM
$MNMD Wait? I thought Pfizer or Merck were buying these guys out?! I'm shorting this until $8..probably goes even lower if the whole market enters bear mode. Watch out fellas! When in doubt, just zoom out! (the 10yr chart tells the real story)
1 · Reply
DonCorleone77
DonCorleone77 Nov. 6 at 10:05 PM
$MNMD Mind Medicine reports Q3 EPS (78c), consensus (50c)
0 · Reply
smile696
smile696 Nov. 6 at 9:51 PM
$MNMD Cash runway into 2028
2 · Reply
AustrianAssassin
AustrianAssassin Nov. 6 at 9:45 PM
$MNMD things are always so confusing…is it a miss at -.78 cents per share?
0 · Reply
MichaelNaussCMT
MichaelNaussCMT Nov. 6 at 9:10 PM
$MNMD earning out initial sweep down but recovering.
1 · Reply
justiceforb_85
justiceforb_85 Nov. 6 at 8:58 PM
$MNMD started a position. MM120 will be a much needed therapeutic in GAD.
1 · Reply
Patjarguello
Patjarguello Nov. 6 at 4:35 PM
$MNMD is this just going to keep dropping?
0 · Reply
Latest News on MNMD
Mind Medicine (MindMed) Inc. (MNMD) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 9:46 PM EST - 12 hours ago

Mind Medicine (MindMed) Inc. (MNMD) Q3 2025 Earnings Call Transcript

MindMed Reports Q3 2025 Financial Results and Business Updates

Nov 6, 2025, 4:01 PM EST - 17 hours ago

MindMed Reports Q3 2025 Financial Results and Business Updates

MindMed to Participate in Upcoming Investor Conferences

Nov 5, 2025, 7:01 AM EST - 2 days ago

MindMed to Participate in Upcoming Investor Conferences

MindMed Announces New Employee Inducement Grant

Nov 3, 2025, 4:01 PM EST - 3 days ago

MindMed Announces New Employee Inducement Grant

Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

Nov 3, 2025, 7:01 AM EST - 4 days ago

Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

MindMed to Report Q3 2025 Financial Results on November 6, 2025

Oct 30, 2025, 4:01 PM EDT - 7 days ago

MindMed to Report Q3 2025 Financial Results on November 6, 2025

Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering

Oct 29, 2025, 10:14 PM EDT - 8 days ago

Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering

Mind Medicine (MindMed) Inc. Announces Proposed Public Offering

Oct 29, 2025, 4:01 PM EDT - 8 days ago

Mind Medicine (MindMed) Inc. Announces Proposed Public Offering

MindMed Nears Pivotal Year: Strong Fundamentals Make It A Buy

Oct 14, 2025, 12:28 PM EDT - 23 days ago

MindMed Nears Pivotal Year: Strong Fundamentals Make It A Buy

Mind Medicine Analyst Cites Strong Phase 3 Pipeline For Anxiety, Depression

Oct 13, 2025, 2:54 PM EDT - 24 days ago

Mind Medicine Analyst Cites Strong Phase 3 Pipeline For Anxiety, Depression

MindMed Announces New Employee Inducement Grants

Sep 22, 2025, 4:01 PM EDT - 6 weeks ago

MindMed Announces New Employee Inducement Grants

New MindMed Retrospective Study Presented at Psych Congress 2025 Reveals High Rates of Suicidal Ideation (SI) in Adults with Generalized Anxiety Disorder (GAD)

Sep 19, 2025, 7:00 AM EDT - 7 weeks ago

New MindMed Retrospective Study Presented at Psych Congress 2025 Reveals High Rates of Suicidal Ideation (SI) in Adults with Generalized Anxiety Disorder (GAD)

Journal of the American Medical Association (JAMA) Publishes Results from First-Ever Randomized, Placebo-Controlled Clinical Trial Assessing the Dose-Dependent Efficacy of MM120 (Lysergide D-Tartrate, LSD) in Generalized Anxiety Disorder (GAD)

Sep 4, 2025, 11:05 AM EDT - 2 months ago

Journal of the American Medical Association (JAMA) Publishes Results from First-Ever Randomized, Placebo-Controlled Clinical Trial Assessing the Dose-Dependent Efficacy of MM120 (Lysergide D-Tartrate, LSD) in Generalized Anxiety Disorder (GAD)

MindMed to Participate in September Investor Conferences

Aug 28, 2025, 7:00 AM EDT - 2 months ago

MindMed to Participate in September Investor Conferences

Mind Medicine (MindMed) Inc. (MNMD) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 9:48 PM EDT - 3 months ago

Mind Medicine (MindMed) Inc. (MNMD) Q2 2025 Earnings Call Transcript

MindMed Reports Q2 2025 Financial Results and Business Updates

Jul 31, 2025, 4:01 PM EDT - 3 months ago

MindMed Reports Q2 2025 Financial Results and Business Updates

MindMed to Report Second Quarter 2025 Financial Results on July 31, 2025

Jul 24, 2025, 7:00 AM EDT - 3 months ago

MindMed to Report Second Quarter 2025 Financial Results on July 31, 2025

MindMed to Participate in June Investor Conferences

May 28, 2025, 7:00 AM EDT - 5 months ago

MindMed to Participate in June Investor Conferences

MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer

May 27, 2025, 7:00 AM EDT - 5 months ago

MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer

MindMed to Present at the 2025 RBC Capital Markets Global Healthcare Conference

May 13, 2025, 7:00 AM EDT - 6 months ago

MindMed to Present at the 2025 RBC Capital Markets Global Healthcare Conference

Mind Medicine (MindMed) Inc. (MNMD) Q1 2025 Earnings Call Transcript

May 8, 2025, 9:55 AM EDT - 6 months ago

Mind Medicine (MindMed) Inc. (MNMD) Q1 2025 Earnings Call Transcript

MindMed Reports First Quarter 2025 Financial Results and Recent Business Updates

May 8, 2025, 7:00 AM EDT - 6 months ago

MindMed Reports First Quarter 2025 Financial Results and Recent Business Updates

MindMed to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 24, 2025, 7:00 AM EDT - 7 months ago

MindMed to Report First Quarter 2025 Financial Results on May 8, 2025

MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD)

Apr 15, 2025, 7:00 AM EDT - 7 months ago

MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD)

MindMed Appoints Matt Wiley as Chief Commercial Officer

Mar 17, 2025, 7:00 AM EDT - 8 months ago

MindMed Appoints Matt Wiley as Chief Commercial Officer

Mind Medicine (MindMed) Inc. (MNMD) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 12:10 PM EST - 8 months ago

Mind Medicine (MindMed) Inc. (MNMD) Q4 2024 Earnings Call Transcript

MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates

Mar 6, 2025, 7:00 AM EST - 8 months ago

MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates

MindMed to Present at Leerink's Global Healthcare Conference 2025

Mar 4, 2025, 7:00 AM EST - 8 months ago

MindMed to Present at Leerink's Global Healthcare Conference 2025

MindMed to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

Feb 20, 2025, 7:00 AM EST - 9 months ago

MindMed to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

MindMed to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 7:00 AM EST - 9 months ago

MindMed to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder

Jan 30, 2025, 7:00 AM EST - 10 months ago

MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder

MindMed to Be Added to the Nasdaq Biotechnology Index

Dec 19, 2024, 7:00 AM EST - 11 months ago

MindMed to Be Added to the Nasdaq Biotechnology Index

MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)

Dec 16, 2024, 7:00 AM EST - 11 months ago

MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)

MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress

Dec 11, 2024, 7:00 AM EST - 11 months ago

MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress

MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)

Dec 5, 2024, 7:00 AM EST - 1 year ago

MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)

MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy

Dec 3, 2024, 7:00 AM EST - 1 year ago

MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy

MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer

Nov 18, 2024, 7:00 AM EST - 1 year ago

MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer

Mind Medicine: No News = Good News

Nov 10, 2024, 9:55 AM EST - 1 year ago

Mind Medicine: No News = Good News

Mind Medicine (MindMed) Inc. (MNMD) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 8:06 PM EST - 1 year ago

Mind Medicine (MindMed) Inc. (MNMD) Q3 2024 Earnings Call Transcript

MindMed Reports Third Quarter 2024 Financial Results and Business Updates

Nov 7, 2024, 4:01 PM EST - 1 year ago

MindMed Reports Third Quarter 2024 Financial Results and Business Updates

Mind Medicine: Two Pathways Created From One Pipeline Clinical Candidate

Nov 4, 2024, 4:04 PM EST - 1 year ago

Mind Medicine: Two Pathways Created From One Pipeline Clinical Candidate

MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2024 Financial Results and Provide Business Update

Oct 24, 2024, 7:00 AM EDT - 1 year ago

MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2024 Financial Results and Provide Business Update

Psychedelic Stocks: Focus On Their Cash

Aug 15, 2024, 12:30 PM EDT - 1 year ago

Psychedelic Stocks: Focus On Their Cash

CMPS

Mind Medicine (MindMed) Inc. (MNMD) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 11:21 AM EDT - 1 year ago

Mind Medicine (MindMed) Inc. (MNMD) Q2 2024 Earnings Call Transcript

MindMed readying Phase III trials for LSD therapy to treat anxiety

Aug 13, 2024, 7:44 AM EDT - 1 year ago

MindMed readying Phase III trials for LSD therapy to treat anxiety

Pacific Defense Announces US Army CMFF Program Team

Aug 13, 2024, 7:01 AM EDT - 1 year ago

Pacific Defense Announces US Army CMFF Program Team

MRNS

MindMed Reports Second Quarter 2024 Financial Results and Business Updates

Aug 13, 2024, 7:00 AM EDT - 1 year ago

MindMed Reports Second Quarter 2024 Financial Results and Business Updates

FDA Rejection of MDMA Therapy Isn't End of Psychedelic-Drug Candidates

Aug 12, 2024, 12:47 PM EDT - 1 year ago

FDA Rejection of MDMA Therapy Isn't End of Psychedelic-Drug Candidates

Psychedelic drug contender stocks drop after FDA rejects MDMA treatment

Aug 12, 2024, 12:12 PM EDT - 1 year ago

Psychedelic drug contender stocks drop after FDA rejects MDMA treatment

ATAI CMPS CYBN

Mind Medicine (MindMed) Inc. Announces Pricing of Public Offering

Aug 9, 2024, 8:44 AM EDT - 1 year ago

Mind Medicine (MindMed) Inc. Announces Pricing of Public Offering

Kaloo_03
Kaloo_03 Nov. 7 at 12:06 AM
$MNMD
1 · Reply
NeedsAwin
NeedsAwin Nov. 6 at 11:24 PM
$MNMD well that was a nothing burger. Not bad not good. Just nothing.
0 · Reply
goral17
goral17 Nov. 6 at 10:52 PM
$MNMD Too much dilution. Too many reverse splits. Too many mumbo jumbo naming of products. Too scammy? I think so... This gets delisted within a couple years! Back to otc! If trump gets a 3rd term I think theyll send this shit BACK to the Canadian exchanges!
1 · Reply
goral17
goral17 Nov. 6 at 10:45 PM
$MNMD Wait? I thought Pfizer or Merck were buying these guys out?! I'm shorting this until $8..probably goes even lower if the whole market enters bear mode. Watch out fellas! When in doubt, just zoom out! (the 10yr chart tells the real story)
1 · Reply
DonCorleone77
DonCorleone77 Nov. 6 at 10:05 PM
$MNMD Mind Medicine reports Q3 EPS (78c), consensus (50c)
0 · Reply
smile696
smile696 Nov. 6 at 9:51 PM
$MNMD Cash runway into 2028
2 · Reply
AustrianAssassin
AustrianAssassin Nov. 6 at 9:45 PM
$MNMD things are always so confusing…is it a miss at -.78 cents per share?
0 · Reply
MichaelNaussCMT
MichaelNaussCMT Nov. 6 at 9:10 PM
$MNMD earning out initial sweep down but recovering.
1 · Reply
justiceforb_85
justiceforb_85 Nov. 6 at 8:58 PM
$MNMD started a position. MM120 will be a much needed therapeutic in GAD.
1 · Reply
Patjarguello
Patjarguello Nov. 6 at 4:35 PM
$MNMD is this just going to keep dropping?
0 · Reply
Beachlife22
Beachlife22 Nov. 6 at 3:48 PM
$MNMD whoa , this market 🩸🩸🩸🛀
0 · Reply
Mcahill
Mcahill Nov. 6 at 2:34 PM
$ATAI $MNMD $CMPS $CYBN Another bloodbath
0 · Reply
Defen
Defen Nov. 6 at 2:11 PM
$MNMD earring supposed to be before the bell today? Nothing yet?
2 · Reply
Doox
Doox Nov. 6 at 8:48 AM
$MNMD Is ER today?
1 · Reply
Mcahill
Mcahill Nov. 5 at 8:55 PM
$ATAI $MNMD $CMPS $CYBN Wow they really fucked us good
3 · Reply
stoxx0007
stoxx0007 Nov. 5 at 8:46 PM
$CMPS $CYBN $MNMD $GHRS $PSIL
1 · Reply
Laynester
Laynester Nov. 5 at 6:55 PM
$NGL $APPS $MNMD $AESI $TAN Now we are logging.... (my dad used to say that when everyone was working hard together....) 100%--->
0 · Reply
stonksmash
stonksmash Nov. 5 at 5:31 PM
$MNMD extremely high risk/reward ratio. 7 days to cover? A surprise could send us 20% or more.. I’m DEEP in 15c going into earnings.
1 · Reply
mcgr
mcgr Nov. 5 at 5:15 PM
$CMPS $CYBN $MNMD $ATAI As a reminder to everyone, if these correct down 20-50%, that’s a phenomenal time to buy. You’ve never been closer to approval, commercialization & revenue than today. I’m praying for a massive dip without any fundamentals changing, love a discount,
0 · Reply
NeedsAwin
NeedsAwin Nov. 5 at 3:38 PM
$MNMD entire sector taking a shit?
0 · Reply
twiggs462
twiggs462 Nov. 5 at 1:46 PM
$MNMD MindMed to Participate in Upcoming Investor Conferences NEW YORK--(BUSINESS WIRE)-- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company’s management team will participate in the following investor conferences: https://www.businesswire.com/news/home/20251105303331/en
0 · Reply
brunoq14
brunoq14 Nov. 5 at 2:42 AM
$MNMD Looks like a good bet to nail the P3 GAD trials and submit for approval end of 2026.
1 · Reply